DSL(SH:603233) SINOLINK SECURITIES·2025-10-30 01:59Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [3][11]. Core Insights - The company achieved a revenue of 20.07 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 1.71%. The net profit attributable to shareholders was 1.08 billion yuan, up 25.97% year-on-year [2]. - In Q3 2025, the company reported a revenue of 6.55 billion yuan, a 2.51% increase year-on-year, with a net profit of 280 million yuan, reflecting a significant year-on-year growth of 41.04% [2]. - The retail segment remained stable with a revenue of 16.34 billion yuan in the first three quarters of 2025, showing a slight decline of 0.07% year-on-year, but benefiting from new and existing store growth [3]. - The company has been expanding its franchise model rapidly, with a total of 17,385 stores by the end of Q3 2025, including 7,029 franchise stores, marking a net increase of 832 stores [3]. - The demand for traditional Chinese and Western medicine remains strong, with revenue in this segment reaching 15.45 billion yuan, a year-on-year increase of 5.01% [3]. - The company has successfully reduced its selling expense ratio to 22.3%, down 2.5 percentage points year-on-year, indicating effective cost management [3]. Financial Forecasts - The company is expected to continue its growth trajectory, with projected net profits of 1.20 billion yuan, 1.39 billion yuan, and 1.57 billion yuan for 2025, 2026, and 2027 respectively, representing year-on-year growth rates of 31.2%, 15.5%, and 13.3% [3]. - Earnings per share (EPS) are forecasted to be 1.05 yuan, 1.22 yuan, and 1.38 yuan for the same years, with corresponding price-to-earnings (P/E) ratios of 17, 15, and 13 times [3][8].